Irritable bowel syndrome: modern ideas about pathology and the possibility of its correction

Among the  defecating disorders  with  constipation or diarrhea,  there  is a  group  of major  intestinal disorders  defined  by the  Rome IV Diagnostic  Criteria (2016): irritable  bowel  syndrome, functional  constipation, functional  diarrhea. The presence of several updates of the Rome criteria is due to the current  lack of objective signs of the listed disorders while many options for describing  subjective  sensation by patients from different  countries. It calls for their terminological multilingual  standardization. Both constipation and diarrhea  can be caused  by a variety of exogenous and endogenous factors and have different pathogenetic mechanisms,  but they cannot  be identified  properly using modern  clinical and laboratory  methods for functional intestinal disorders. However, the  high prevalence of these  syndromes, characterized by the  presence of complaints  that reduce  patients’ quality of life, necessitates their  correction. The drug choice for defecation disorders  and abdominal  pain is often limited by contradictions from international clinical guidelines and national  regulations.Therefore, the Recommendations of the  Russian Gastroenterological Association for the  treatment of functional  intestinal diseases  contain  many instructions on general  therapeutic and dietary measures. The pain syndrome treatment is based on the spasmolytics. Among the laxatives that  have long been  used in the treatment of chronic constipation, sodium picosulfate has long been  successfully used. This drug has high efficacy and safety profiles; the instructions for its medical  use allow to prescribe  it in patients suffered  from irritable  bowel syndrome with constipation. The use of sodium picosulfate for IBS is regulated by many clinical recommendations. However, this  drug  may be ineffective  against  abdominal  pain. It is incorrect  to assign  the  mission  of pain  relief  to a laxative  because of multifactorial pathogenesis of IBS pain with constipation or diarrhea  and uncertainty of methods for its pharmacological control.

1. Wright PS, Thomas SL. Constipation and diarrhea: the neglected symptoms. Semin Oncol Nurs. 1995;11(4):289–297. https://doi.org/10.1016/s0749-2081(05)80010-5.

2. Donatelle EP. Constipation: pathophysiology and treatment. Am Fam Physician. 1990;42(5):1335–1342. Available at: https://pubmed.ncbi.nlm.nih.gov/2239640.

3. Weinrich SP, Blesch KS, Dickson GW, Nussbaum JS, Watson EJ. Timely detection of colorectal cancer in the elderly. Implications of the aging process. Cancer Nurs. 1989;12(3):170–176. Available at: https://pubmed.ncbi.nlm.nih.gov/2743300.

4. McCance KL, Huether SE. Pathophysiology: The Biologic Basis for Disease in Adults and Children. 2nd ed. St Louis: Mosby; 1994. 1704 p. Available at: https://archive.org/details/pathophysiology00kath/page/n1/mode/2up.

5. Lipsky MS, Adelman M. Chronic diarrhea: evaluation and treatment. Am Fam Physician. 1993;48(8):1461–1466. Available at: https://pubmed.ncbi.nlm.nih.gov/8249777.

6. Drossman DA, Hasler WL. Rome IV-Functional GI Disorders: Disorders of Gut-Brain Interaction. Gastroenterology. 2016;150(6):1257–1261. https://doi.org/10.1053/j.gastro.2016.03.035.

7. Trukhan DI, Goloshubina VV. Irritable bowel syndrome: current aspects of etiology, pathogenesis, clinic and treatment: A review. Consilium Medicum. 2022;24(5):297–305. (In Russ.) https://doi.org/10.26442/20751753.2022.5.201861.

8. Lacy BE, Mearin F, Chang L, Chey WD, Lembo AJ, Simren M, Spiller R. Bowel Disorders. Gastroenterology. 2016;S0016-5085(16)00222-5. https://doi.org/10.1053/j.gastro.2016.02.031.

9. Samsonov AA, Kucheryavyi YuA, Andreev DN. Chronic constipation: problems of therapy. Vrach. 2011;(4):24–29. (In Russ.) Available at: https://elibrary.ru/nedrhz.

10. Drozdov VN, Karnouh KI, Serebrova SY, Komissarenko IA, Starodubtsev AK. Possibilities of sodium picosulfate application in constipation pharmacotherapy in functional intestinal disorders. Meditsinskiy Sovet. 2019;(3):92–97. (In Russ.) https://doi.org/10.21518/2079-701X-2019-3-92-97.

11. Ivashkin VT, Maev IV, Shelygin YuA, Baranskaya EK, Belous SS, Belousova EA et al. Diagnosis and Treatment of Irritable Bowel Syndrome: Clinical Recommendations of the Russian Gastroenterological Association and Association of Coloproctologists of Russia. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(5):74–95. (In Russ.) https://doi.org/10.22416/1382-4376-2021-31-5-74-95.

12. Tuck CJ, Taylor KM, Gibson PR, Barrett JS, Muir JG. Increasing Symptoms in Irritable Bowel Symptoms With Ingestion of Galacto-Oligosaccharides Are Mitigated by α-Galactosidase Treatment. Am J Gastroenterol. 2018;113(1):124–134. https://doi.org/10.1038/ajg.2017.245.

13. Johannesson E, Ringström G, Abrahamsson H, Sadik R. Intervention to increase physical activity in irritable bowel syndrome shows long-term positive effects. World J Gastroenterol. 2015;21(2):600–608. https://doi.org/10.3748/wjg.v21.i2.600.

14. Ford AC, Moayyedi P, Lacy BE, Lembo AJ, Saito YA, Schiller LR et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014;109(Suppl 1):S2–S27. https://doi.org/10.1038/ajg.2014.187.

15. Hou X, Chen S, Zhang Y, Sha W, Yu X, Elsawah H et al. Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBS-Quality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: results of an international prospective observational cohort study in Poland, Egypt, Mexico and China. Clin Drug Investig. 2014;34(11):783–793. https://doi.org/10.1007/s40261-014-0233-y.

16. Farack UM, Gruber E, Loeschke K. The influence of bisacodyl and deacetyl-bisacodyl on mucus secretion, mucus synthesis and electrolyte movements in the rat colon in vivo. Eur J Pharmacol. 1985;117(2):215–222. https://doi.org/10.1016/0014-2999(85)90606-5.

17. Mueller-Lissner S, Kamm MA, Wald A, Hinkel U, Koehler U, Richter E, Bubeck J. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of sodium picosulfate in patients with chronic constipation. Am J Gastroenterol. 2010;105(4):897–903. https://doi.org/10.1038/ajg.2010.41.